Lilly’s Oral GLP-1 Foundayo Wins FDA Approval, Intensifying Obesity Drug Market Competition
- nuaxia
- Apr 2
- 1 min read
New oral weight-loss treatment enters the market as competition with Novo Nordisk’s oral Wegovy accelerates.
The FDA has approved Eli Lilly’s oral GLP-1 drug Foundayo (orforglipron) for weight management, supported by Phase III trial data showing significant weight loss in patients.
The approval marks a major step in the growing oral obesity treatment market, setting up increased competition with Novo Nordisk’s oral semaglutide.
Alert Type | FDA Approval |
Drug/Device Name | Foundayo (orforglipron) |
Indication | Chronic weight management / Obesity |
Therapy Area(s) | Obesity, Metabolic, Endocrinology |
Geography | United States |
What Changed | The FDA approved Eli Lilly’s oral GLP-1 agonist Foundayo (orforglipron) for weight management, becoming the first new molecular entity approved under the FDA Commissioner’s National Priority Voucher programme. The approval was supported by Phase III ATTAIN-1 trial data showing up to 12.4% weight loss at 72 weeks. |
Clinical Relevance | Provides a new oral GLP-1 treatment option for obesity that can be taken without food or water restrictions, potentially improving adherence and expanding access compared with existing oral GLP-1 therapies. |
Source Link | |
Date | 2-Apr-2026 |
Status | Draft |
Notes | Competes directly with Novo Nordisk’s oral semaglutide (Wegovy). Label includes simvastatin dosing considerations. Analysts forecast strong sales growth and major competition in oral obesity market. |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments